Valuation: Guided Therapeutics Inc

Market Cap 25.1M 22.07M 20.31M 19.03M 35.62M 2.37B 36.33M 244M 94.47M 1.17B 94.24M 92.18M 4.06B P/E 2024
-3x
P/E 2025 -12.7x
Enterprise Value 27.98M 24.6M 22.63M 21.21M 39.7M 2.64B 40.5M 272M 105M 1.3B 105M 103M 4.53B EV / Sales 2024
1,649x
EV / Sales 2025 64.4x
Free-Float
63.48%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 70 2023-03-05
Chief Tech/Sci/R&D Officer 70 2010-12-01
Director TitleAgeSince
Director/Board Member 70 2016-11-30
Director/Board Member 76 2006-04-09
Chairman 67 2013-09-30
Change 5-day change 1-year change 3-year change Capi.($)
+13.33%-.--% - - 25.1M
+2.75%+9.54%+25.07%-3.52% 183B
-0.53%-0.62%-23.59%+22.13% 142B
+2.30%+8.69%-2.16%-18.88% 134B
-0.58%-1.67%-57.55%-18.10% 66.08B
+0.07%+3.51%+18.29%-0.69% 51.63B
+0.50%-0.72%-26.65%-32.86% 43.38B
+2.95%+8.99%+15.19%+13.47% 37.18B
+2.09%+5.57%+8.68%+45.05% 36.25B
+0.09%+6.20%-9.78%-18.64% 29.51B
Average +2.30%+2.91%-5.83%-1.34% 80.33B
Weighted average by Cap. +1.26%+2.05%-3.44%-1.51%

Financials

2024 2025
Net sales 7K 6.16K 5.66K 5.31K 9.93K 661K 10.13K 68.02K 26.35K 325K 26.28K 25.71K 1.13M 767K 674K 621K 581K 1.09M 72.39M 1.11M 7.45M 2.89M 35.67M 2.88M 2.82M 124M
Net income -2.42M -2.13M -1.96M -1.83M -3.43M -228M -3.5M -23.49M -9.1M -112M -9.08M -8.88M -391M -3.2M -2.81M -2.59M -2.42M -4.54M -302M -4.63M -31.06M -12.03M -149M -12M -11.74M -517M
Net Debt 1.77M 1.56M 1.43M 1.34M 2.51M 167M 2.56M 17.21M 6.67M 82.35M 6.65M 6.5M 287M 2.88M 2.53M 2.33M 2.18M 4.08M 271M 4.16M 27.95M 10.82M 134M 10.8M 10.56M 465M
Logo Guided Therapeutics Inc
Guided Therapeutics, Inc. is a medical technology company. The Company is focused on developing medical devices that have the potential to improve healthcare. The Company’s primary focus is the sales and marketing of its LuViva Advanced Cervical Scan non-invasive cervical cancer detection device. The underlying technology of LuViva primarily relates to the use of biophotonics for the non-invasive detection of cancers. LuViva is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point of care by scanning the cervix with light, then analyzing the reflected and fluorescent light. LuViva is designed to provide a less invasive and painless alternative to conventional tests for cervical cancer screening and detection. Additionally, LuViva is designed to improve patient well-being not only because it eliminates pain, but also because it is convenient to use and provides rapid results at the point of care.
Employees
-